Day 3 embryo quality predicts clinical pregnancy and live birth rates following single frozen–thawed poor‐quality blastocyst transfer
International Journal of Gynecology & Obstetrics · 2026-08 · 174 (2) · 961-967
DOI: 10.1002/ijgo.70916 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 26.02.2026. Verfasst von Li Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center of Reproductive Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong Province, China. Hauptthemen laut MEDLINE: Live Birth, Blastocyst, Embryo Transfer. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guangzhou Municipal Science and Technology Program key projects.
Abstract (Originalsprache)
Objective
This study explored the value of Day 3 embryo quality in selecting blastocysts of the same grade, with a specific focus on poor‐quality blastocysts.
Methods
This retrospective study included 734 single frozen–thawed blastocyst transfer cycles from January 2018 to October 2021. Cycles were categorized into four groups based on embryo quality: the G‐G group (good‐quality blastocysts derived from Day 3 good‐quality embryos group, n = 194), the G‐P group (good‐quality blastocysts derived from Day 3 poor‐quality embryos group, n = 230), the P‐G group (poor‐quality blastocysts derived from Day 3 good‐quality embryos group, n = 94), and the P‐P group (poor‐quality blastocysts derived from Day 3 poor‐quality embryos group, n = 216). The role of Day 3 embryo quality in selecting blastocysts for transfer was analyzed.
Results
Good‐quality blastocysts derived from Day 3 poor‐quality embryos showed comparable pregnancy outcomes to those derived from Day 3 good‐quality embryos (clinical pregnancy rates: 63.91% vs. 65.98%; live birth rates: 53.04% vs. 55.15%, respectively; P > 0.05). However, poor‐quality blastocysts derived from Day 3 good‐quality embryos exhibited significantly higher clinical pregnancy rates (58.51% vs. 37.96%, P < 0.01; odds ratio [OR] 2.006, 95% CI 1.185–3.395, P < 0.05) and live birth rates (52.13% vs. 28.70%, P < 0.001; OR 2.318, 95% CI 1.355–3.966, P < 0.01) than those derived from Day 3 poor‐quality embryos. Conclusion(s) Day 3 embryo quality predicts clinical pregnancy and live birth rates following single frozen–thawed poor‐quality blastocyst transfer. When only poor‐quality blastocysts are obtained, selecting one derived from Day 3 good‐quality embryo for transfer might shorten the time to achieve a live birth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Reproductive Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Förderung
- Guangzhou Municipal Science and Technology Program key projects
Zitieren
APA
Yang, L., Yin, M., Sun, L., Wang, H., Liang, Y., Wu, H., Jiang, Y., Li, M., Wu, Z., Chen, Z., & Liu, S. (2026). Day 3 embryo quality predicts clinical pregnancy and live birth rates following single frozen–thawed poor‐quality blastocyst transfer. International Journal of Gynecology & Obstetrics, 174(2), 961-967. https://doi.org/10.1002/ijgo.70916
Vancouver
Yang L, Yin M, Sun L, Wang H, Liang Y, Wu H, et al. Day 3 embryo quality predicts clinical pregnancy and live birth rates following single frozen–thawed poor‐quality blastocyst transfer. International Journal of Gynecology & Obstetrics. 2026;174(2):961-967. doi:10.1002/ijgo.70916
BibTeX
@article{Yang2026,
author = {Yang, Li and Yin, Minna and Sun, Ling and Wang, Hui and Liang, Yunhao and Wu, Huijiao and Jiang, Yu and Li, Meiyi and Wu, Zhufeng and Chen, Zhiheng and Liu, Shuai},
title = {Day 3 embryo quality predicts clinical pregnancy and live birth rates following single frozen–thawed poor‐quality blastocyst transfer},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
volume = {174},
number = {2},
pages = {961--967},
doi = {10.1002/ijgo.70916}
}
EUVIMED